Clinical trials: Depressive State
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics…
- Trial name
- NCT00330616
- Testing
- 323U66 SR
- Where
- 9 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Depression, Anxiety
Feasibility and Acceptability of W-GenZD vs CBT-light Teletherapy for Adolescents Seeking Mental Health Services
The primary aim of this study is to determine the feasibility and acceptability of the W-GenZD mobile application among a group of adolescents and who have screened and triaged into low-intensity treatment within the Children's…
- Trial name
- NCT05372913
- Testing
- Woebot for Adolescents (W-GenZD) Mobile Application, CBT-Lite Teletherapy Group
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Woebot Health
Bipolar Depression
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868959
- Testing
- lurasidone
- Where
- 151 sites in United States, Canada and 13 more
- Volunteers
- 817 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder
A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.
This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed.
- Trial name
- NCT00282464
- Testing
- Geodon (Ziprasidone)
- Where
- 43 sites in United States
- Volunteers
- 392 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal…
- Trial name
- TRANSFORM-1 (NCT02417064)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 90 sites in United States, Belgium and 7 more
- Volunteers
- 346 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- orvepitant MDD (NCT00880399)
- Testing
- orvepitant
- Where
- 20 sites in United States, Canada
- Volunteers
- 328 people
- Sponsor
- GlaxoSmithKline
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
This study investigates two different approaches to the change in antidepressant treatment when an initial treatment is not effective: early intervention or delayed intervention. Two hypothesis will be tested: 1.
- Trial name
- NCT00810069
- Testing
- Duloxetine Hydrochloride, Escitalopram
- Where
- 60 sites in Denmark, France and 9 more
- Volunteers
- 840 people
- Sponsor
- Eli Lilly and Company
Major Depression
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
The primary purpose of this study is to investigate medication utilization pattern and risk of adverse outcomes among commonly used antidepressants by using nationwide claims database, in order to assess overall clinical benefit…
- Trial name
- NCT04446039
- Testing
- Escitalopram, Paroxetine, Fluoxetine
- Where
- South Korea
- Volunteers
- 370,212 people
- Sponsor
- Pfizer
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Severe Postpartum Depression
A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum…
- Trial name
- NCT02614547
- Testing
- SAGE-547
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Depressive Disorder, Major
Switching to Duloxetine in Patients With Depression
The purpose of this study is to help answer the following research question: Whether switching to duloxetine improves depressed mood when current treatment did not work well for patients with depression.
- Trial name
- ARDENT (NCT00696774)
- Testing
- Duloxetine
- Where
- 2 sites in South Korea
- Volunteers
- 242 people
- Sponsor
- Eli Lilly and Company
Depression
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD)…
- Trial name
- NCT02918318
- Testing
- Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg)
- Where
- 43 sites in Japan
- Volunteers
- 202 people
- Sponsor
- Janssen Pharmaceutical K.K.
Major Depressive Disorder
A Study in Depression and Associated Painful Physical Symptoms
The purpose of this study is to find out if 60 mg of duloxetine given once a day by mouth for 8 weeks to patients diagnosed with major depressive disorder, who also report associated painful physical symptoms, is better than…
- Trial name
- NCT01070329
- Testing
- Duloxetine
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC